Cipla (CIPLA) Weekly Analysis
Price & Volume
The stock price rose by 4.37% this week, continuing a positive streak that has now lasted for three consecutive weeks. Trading activity was notably higher, with total volume increasing by 60.84% compared to the previous week. The stock price closed at 1295.0, successfully moving above its 50-day moving average.
Technicals
The stock closed at 1295.0, reflecting a 4.37% increase over the week. The Relative Strength Index (RSI), which measures the speed and change of price movements, rose to 60.61, indicating strengthening momentum. The MACD, a tool used to identify trend direction and momentum, shows a positive histogram of 12.84, suggesting bullish momentum. Moving averages, which smooth out price data to show trends, remain in a downward slope. Bollinger Band width, a measure of volatility, is at 9.03%. The technical regime is currently characterized by rising momentum against a backdrop of downward-sloping long-term price trends.
Fundamentals
Cipla has demonstrated strong long-term growth, with net profit achieving a 27.4% 3-year CAGR (compound annual growth rate, representing the mean annual growth over three years). For the fiscal year ending March 2025, the company reported revenue of ₹27,548 crore and a net profit of ₹5,269 crore, reflecting a 26.8% YoY (year-over-year) increase in profit. Current profitability remains robust, with a TTM (trailing twelve-month) net profit margin of 16.0%. The company has maintained a disciplined balance sheet, evidenced by a very low net debt to EBITDA ratio of 0.1 as of March 2025. These figures reflect consistent operational efficiency and solid financial health over the recent multi-year period.
News
On April 23, 2026, Cipla experienced a significant market development following the USFDA approval of its generic version of the Ventolin inhaler, a move that allows the company to compete in a $1.5 billion market. This regulatory milestone triggered a nearly 5% jump in the company's stock price. Despite this positive catalyst, technical indicators shifted to a bearish outlook by April 22, 2026, as the stock faced increased market pressure and a surge in open interest. By April 24, 2026, financial analysts remained divided regarding the company's future performance, citing potential execution risks despite the favorable product launch. Consequently, while some brokerages maintained optimistic price targets, the overall market sentiment reflected a cautious stance on the company's near-term trajectory.
Events
Cipla has received USFDA approval for its Albuterol Sulfate Inhalation Aerosol, the first AB-rated generic equivalent to Ventolin HFA. The product is scheduled for launch in the U.S. market during the first half of FY 2026-27.
Cipla Limited announced that the USFDA concluded a cGMP and Pre-Approval Inspection at its Verna, Goa manufacturing facility, resulting in two inspectional observations in Form 483.
Cipla Limited has scheduled an earnings conference call for May 13, 2026, to discuss its audited financial results for the quarter ended March 31, 2026.
Cipla Limited has published newspaper advertisements regarding the IEPFA's 'Saksham Niveshak' campaign, which encourages shareholders to claim unpaid dividends and update their KYC details. This initiative aims to assist investors in recovering their unclaimed financial assets.
Cipla Limited has submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2026, as received from its Registrar and Share Transfer Agent, KFin Technologies Limited.
Cipla Limited announced that the USFDA concluded a cGMP and Pre-Approval Inspection at its Verna, Goa manufacturing facility, resulting in two inspectional observations in Form 483.
Cipla Limited has scheduled an earnings conference call for May 13, 2026, to discuss its audited financial results for the quarter ended March 31, 2026.
Cipla Limited has published newspaper advertisements regarding the IEPFA's 'Saksham Niveshak' campaign, which encourages shareholders to claim unpaid dividends and update their KYC details. This initiative aims to assist investors in recovering their unclaimed financial assets.
Cipla Limited has submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2026, as received from its Registrar and Share Transfer Agent, KFin Technologies Limited.
Weekly Snapshot
Highlights
- The stock price increased by 4.37% this week, marking the third consecutive week of positive performance.
- Trading activity surged significantly, with total volume rising by 60.84% compared to the previous week.
- The Relative Strength Index (RSI), which measures the speed and change of price movements, rose to 60.61, indicating strengthening momentum.
- Cipla received USFDA approval for its generic version of the Ventolin inhaler, a product used in a large market.
- The company maintains a strong financial position with a low net debt to EBITDA ratio of 0.1 as of March 2025.
What This Means
Cipla experienced a week of positive price action and increased trading volume, supported by the USFDA approval of a generic inhaler product. Technical indicators like the RSI show strengthening momentum, although the stock remains below its 200-day moving average. The company continues to demonstrate solid financial health, characterized by consistent profit growth and a low debt burden.
Latest Quarter Info
For the quarter ending December 2025, the company reported revenue of 7,074, reflecting a slight year-over-year increase but a sequential decline of approximately 6.8%. Operating profitability remained stable at an 18% margin, supported by 1,255 in operating profit against 5,819 in expenses. However, bottom-line performance faced significant pressure, with net profit and earnings per share experiencing sharp double-digit declines on both a quarter-over-quarter and year-over-year basis. This divergence between stable operating margins and declining net profitability highlights the impact of non-operating factors, including negative other income and tax liabilities, on the final earnings outcome for the period.